New hope for controlling a serious autoimmune disease
NCT ID NCT07377058
Summary
This study is testing whether the drug tocilizumab can help control symptoms and lung problems in adults with a specific, serious form of dermatomyositis (anti-MDA5+). Researchers will compare the drug to a placebo (inactive substance) in 110 participants to see if it improves skin/muscle symptoms and breathing. Participants will receive injections every two weeks for two months and have regular checkups to monitor safety and effectiveness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.